Special Issue "Glioma: Molecular Aspects and Theranostics"
Deadline for manuscript submissions: 29 October 2021.
Interests: Glioma; Glioblastoma; Heterogeneity; Tumor Markers; Theranostics; Antibodies; Aptamers; Nuclei Acids Therapeutics; Nucleic Acids-Protein Interactions; PET; Receptors; Glioma Stem Cells; Radiotherapy; Chemotherapy
A success in glioma treatment is very modest, and these tumors remain incurable. Inter- and intra-tumoral heterogeneity are essential features of glioma. Besides, glioma cancer stem cells supply additional variability to the cell populations. Applying a targeted therapy for aggressive clones of the tumor, fates of these clones have to be followed, for example, by studying a possibility to eradicate them.
Application of theranostics to treat glioma requires developing at least two arms of research. Firstly, it is a discovery and a verification of more diagnostics and prognostics molecular biomarkers, including circulating biomarkers in liquid biopsies, in addition to the conventional ones. Secondly, it is a development of elements able to recognize these markers, both molecular recognition elements (MoREs) and cellular recognition elements (CeREs, like CAR T cells). Different theranostic MoREs are monoclonal antibodies; therapeutic peptides; protein scaffolds; aptamers, crypto-aptamers (like G-quadruplexes), pseudo-aptamers. Besides, MoREs could be supplied with additional active molecular modules, both in ensembles and as conjugates; they could be a part of supramolecular nano constructs. The application of different therapeutic nucleic acids and their complexes, including editing complexes and viruses is an attractive supplement. Combinations of theranostics with conventional chemo- and radio-therapies are also will be considered.
The success in glioma treatment to date has been very modest, and these tumors remain incurable. Inter- and intratumoral heterogeneity are essential features of glioma. Additionally, glioma cancer stem cells supply additional variability to the cell populations. To apply a targeted therapy to aggressive clones of the tumor, the fates of these clones have to be followed, for example, by studying the possibility of eradicating them.
The application of theranostics to treat glioma requires developing at least two arms of research. The first arm includes the discovery and verification of more diagnostics and prognostics of molecular biomarkers, including circulating biomarkers in liquid biopsies, in addition to conventional ones. The second includes the development of elements which are able to recognize these markers, both molecular recognition elements (MoREs) and cellular recognition elements (CeREs, like CAR T cells). Different theranostic MoREs include monoclonal antibodies, therapeutic peptides, protein scaffolds, aptamers, crypto-aptamers (such as G-qudruplexes), and pseudo-aptamers. Further, MoREs could be supplied with additional active molecular modules, both in ensembles and as conjugates; they could also be a part of supramolecular nanoconstructs. Application of different therapeutic nucleic acids and their complexes, including editing complexes and viruses, is an attractive supplement. Combinations of theranostics with conventional chemo- and radiotherapies will also be considered.
The Special Issue aims to gather ongoing research on molecular aspects of glioma, including growth factor receptor signal transduction involved in malignant cell survival, proliferation, and invasion, as well as inter- and intratumoral heterogeneity. It will focus on the discovery and verification of molecular markers essential for exploring new targets and development of novel personalized theranostic approaches.
The goal is to gather the data collected by researchers and clinicians to provide a systemic view on glioma. We welcome articles in glioma, including topics on neuropathology/genetics, models of glioma, and investigational therapies.
Prof. Dr. Alexey Kopylov
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Molecular recognition
- Nucleic acids
- Protein scaffolds
- Animal model
- Cell culture
- Signal transduction
- Cancer heterogeneity
- Stem cells
- DNA damage responses
- Target therapy
- Signal transduction
- Receptor signaling
- Growth factors
- Antibody–drug conjugate (ADC)